Previous 10 | Next 10 |
United Therapeutics Corporation (UTHR) Q3 2022 Earnings Conference Call November 02, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer Michael Benkowitz – P...
United Therapeutics ( NASDAQ: UTHR ) stock soared ~12% on Wednesday after Q3 results surpassed analysts estimates. GAAP EPS rose +43.57% Y/Y to $4.91. Total revenues grew +16% Y/Y to $516M. "We are thrilled to report the highest quarterly revenue in our his...
United Therapeutics press release ( NASDAQ: UTHR ): Q3 GAAP EPS of $4.91 beats by $1.10 . Revenue of $516M (+16.0% Y/Y) beats by $22.54M . “We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvas...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third qu...
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 31 st Annual Health...
United Therapeutics ( NASDAQ: UTHR ) said a short induction of Remodulin (treprostinil) injection allowed patients to reach double the typical doses of its other drug Orenitram (treprostinil) extended-release tablets than patients who did not have a Remodulin induction. ...
A short induction of Remodulin ® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram ® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction United Therapeutics Corporation (N...
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022. United Therapeutics will host a public webcast Wednesday, November 2, 2022, at 9:00 a.m. Eastern Time. ...
Data from the INCREASE open label extension study of Tyvaso ® detail its long-term safety and tolerability in pulmonary hypertension associated with interstitial lung disease Data from the FREEDOM-EV open label extension study of Orenitram ® details a...
Second registration study of Tyvaso ® (treprostinil) Inhalation Solution for patients with IPF United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...